BACKGROUND: Carcinoids are rare neuroendocrine tumors (NET). Familial clusterings of NETs are rarely reported, except for a small proportion associated with multiple endocrine neoplasia syndrome type 1. We evaluated the effect of positive family history of NET as well as other cancers on the development of NETs arising at five different locations. METHODS: We conducted a retrospective, hospital-based, case-control study involving 740 patients with histologically confirmed NETs and 924 healthy controls. Information on family history of cancer was collected, and unconditional logistic regression analysis was used to determine adjusted odds ratios (AOR) and 95% confidence intervals (CI). RESULTS: The authors observed a significant relationship between first-degree relatives with cancers and the development of NETs arising at the small intestine, stomach, lung, and pancreas; AORs (95% CI) were 1.6 (1.1-2.4), 2.5 (1.1-6.3), 2.6 (1.5-4.5), and 1.8 (1.1-3.1), respectively. A first-degree family history of esophageal cancer was significantly associated with pancreatic NETs; AOR, 5.6 (95% CI, 1.1-29.6). There was a 70% and 130% increased risk of developing small intestinal NETs among subjects with family histories of colorectal cancer and prostate cancer, respectively. Moreover, individuals with a family history of lung cancer had a 2-fold increase in risk of developing pulmonary NETs. CONCLUSIONS: Having a first-degree relative with any cancer in general, and NET in particular, was a risk factor for NETs. The elevated risk of developing NETs extended to individuals with a family history of other cancers (not NETs) among first-degree relatives. These results suggested that risk of NETs may be partially explained by genetic factors.
BACKGROUND: Carcinoids are rare neuroendocrine tumors (NET). Familial clusterings of NETs are rarely reported, except for a small proportion associated with multiple endocrine neoplasia syndrome type 1. We evaluated the effect of positive family history of NET as well as other cancers on the development of NETs arising at five different locations. METHODS: We conducted a retrospective, hospital-based, case-control study involving 740 patients with histologically confirmed NETs and 924 healthy controls. Information on family history of cancer was collected, and unconditional logistic regression analysis was used to determine adjusted odds ratios (AOR) and 95% confidence intervals (CI). RESULTS: The authors observed a significant relationship between first-degree relatives with cancers and the development of NETs arising at the small intestine, stomach, lung, and pancreas; AORs (95% CI) were 1.6 (1.1-2.4), 2.5 (1.1-6.3), 2.6 (1.5-4.5), and 1.8 (1.1-3.1), respectively. A first-degree family history of esophageal cancer was significantly associated with pancreatic NETs; AOR, 5.6 (95% CI, 1.1-29.6). There was a 70% and 130% increased risk of developing small intestinal NETs among subjects with family histories of colorectal cancer and prostate cancer, respectively. Moreover, individuals with a family history of lung cancer had a 2-fold increase in risk of developing pulmonary NETs. CONCLUSIONS: Having a first-degree relative with any cancer in general, and NET in particular, was a risk factor for NETs. The elevated risk of developing NETs extended to individuals with a family history of other cancers (not NETs) among first-degree relatives. These results suggested that risk of NETs may be partially explained by genetic factors.
Authors: Simon Schimmack; Bernhard Svejda; Benjamin Lawrence; Mark Kidd; Irvin M Modlin Journal: Langenbecks Arch Surg Date: 2011-01-28 Impact factor: 3.445
Authors: Michele L Coté; Mei Liu; Stefano Bonassi; Monica Neri; Ann G Schwartz; David C Christiani; Margaret R Spitz; Joshua E Muscat; Gad Rennert; Katja K Aben; Angeline S Andrew; Vladimir Bencko; Heike Bickeböller; Paolo Boffetta; Paul Brennan; Hermann Brenner; Eric J Duell; Eleonora Fabianova; John K Field; Lenka Foretova; Søren Friis; Curtis C Harris; Ivana Holcatova; Yun-Chul Hong; Dolores Isla; Vladimir Janout; Lambertus A Kiemeney; Chikako Kiyohara; Qing Lan; Philip Lazarus; Jolanta Lissowska; Loic Le Marchand; Dana Mates; Keitaro Matsuo; Jose I Mayordomo; John R McLaughlin; Hal Morgenstern; Heiko Müeller; Irene Orlow; Bernard J Park; Mila Pinchev; Olaide Y Raji; Hedy S Rennert; Peter Rudnai; Adeline Seow; Isabelle Stucker; Neonila Szeszenia-Dabrowska; M Dawn Teare; Anne Tjønnelan; Donatella Ugolini; Henricus F M van der Heijden; Erich Wichmann; John K Wiencke; Penella J Woll; Ping Yang; David Zaridze; Zuo-Feng Zhang; Carol J Etzel; Rayjean J Hung Journal: Eur J Cancer Date: 2012-03-19 Impact factor: 9.162
Authors: Monica Ter-Minassian; Zhaoxi Wang; Kofi Asomaning; Michael C Wu; Chen-Yu Liu; Jessica K Paulus; Geoffrey Liu; Penelope A Bradbury; Rihong Zhai; Li Su; Christine S Frauenhoffer; Susanne M Hooshmand; Immaculata De Vivo; Xihong Lin; David C Christiani; Matthew H Kulke Journal: Carcinogenesis Date: 2011-05-23 Impact factor: 4.944
Authors: Thorvardur R Halfdanarson; William R Bamlet; Robert R McWilliams; Timothy J Hobday; Patrick A Burch; Kari G Rabe; Gloria M Petersen Journal: Pancreas Date: 2014-11 Impact factor: 3.327
Authors: Yeting Du; Monica Ter-Minassian; Lauren Brais; Nichole Brooks; Amanda Waldron; Jennifer A Chan; Xihong Lin; Peter Kraft; David C Christiani; Matthew H Kulke Journal: Endocr Relat Cancer Date: 2016-08 Impact factor: 5.678